|
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
|
|
|
Emergent BioSolutions Reports First Quarter 2024 Financial Results
|
|
|
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
|
|
|
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
|
|
|
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
|
|
|
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
|
|
|
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
|
|
|
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
|
|
|
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
|
|
|
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
|
|
|
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
|
|
|
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
|
|
|
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
|
|